{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:31:10Z","timestamp":1793399470068,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-03005-z","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:14:38Z","timestamp":1785762878000},"page":"3451-3462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and metabolic characteristics of acquired partial lipodystrophy: insights from a multicenter study"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-8919","authenticated-orcid":false,"given":"Basak","family":"Ozgen Saydam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6801-8499","authenticated-orcid":false,"given":"Ilg\u0131n","family":"Yildirim Simsir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4093-7888","authenticated-orcid":false,"given":"Berna","family":"Demir Yuksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0417-7770","authenticated-orcid":false,"given":"Canan","family":"Altay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7494-1562","authenticated-orcid":false,"given":"Nusret","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6937-0865","authenticated-orcid":false,"given":"Sedat","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-3805","authenticated-orcid":false,"given":"Umit","family":"Cavdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5459-366X","authenticated-orcid":false,"given":"Ozlem","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5605-4265","authenticated-orcid":false,"given":"Muge","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4575-5653","authenticated-orcid":false,"given":"Senay","family":"Topsakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0719-988X","authenticated-orcid":false,"given":"Nilufer","family":"Ozdemir Kutbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4618-0273","authenticated-orcid":false,"given":"Secil","family":"Ozisik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9220-6118","authenticated-orcid":false,"given":"Seher","family":"Tanrikulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-1144","authenticated-orcid":false,"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8634-4845","authenticated-orcid":false,"given":"Baris","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"2","key":"3005_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0002-9343(99)00414-3","volume":"108","author":"A Garg","year":"2000","unstructured":"Garg A (2000) Lipodystrophies. Am J Med 108(2):143\u2013152","journal-title":"Am J Med"},{"key":"3005_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.molimm.2019.05.011","volume":"112","author":"F Corvillo","year":"2019","unstructured":"Corvillo F, Akinci B (2019) An overview of lipodystrophy and the role of the complement system. Mol Immunol 112:223\u2013232","journal-title":"Mol Immunol"},{"issue":"1-2","key":"3005_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/07435800.2018.1513029","volume":"44","author":"B Ozgen Saydam","year":"2019","unstructured":"Ozgen Saydam B, Sonmez M, Simsir IY, Erturk MS, Kulaksizoglu M, Arkan T et al (2019) A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities. Endocr Res 44(1\u20132):46\u201354","journal-title":"Endocr Res"},{"issue":"6","key":"3005_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/ijo.2009.286","volume":"34","author":"KN Manolopoulos","year":"2010","unstructured":"Manolopoulos KN, Karpe F, Frayn KN (2010) Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 34(6):949\u2013959","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"3005_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41387-024-00260-y","volume":"14","author":"WJ Loh","year":"2024","unstructured":"Loh WJ, Yaligar J, Hooper AJ, Sadananthan SA, Kway Y, Lim SC et al (2024) Clinical and imaging features of women with polygenic partial lipodystrophy: a case series. Nutr Diabetes 14(1):3","journal-title":"Nutr Diabetes"},{"issue":"11","key":"3005_CR6","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1111\/dom.15882","volume":"26","author":"A Fernandez-Pombo","year":"2024","unstructured":"Fernandez-Pombo A, Yildirim Simsir I, Sanchez-Iglesias S, Ozen S, Castro AI, Atik T et al (2024) A cohort analysis of familial partial lipodystrophy from two Mediterranean countries. Diabetes Obes Metab 26(11):4875\u20134886","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3005_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","volume":"83","author":"A Misra","year":"2004","unstructured":"Misra A, Peethambaram A, Garg A (2004) Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 83(1):18\u201334","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"3005_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.metabol.2015.06.004","volume":"64","author":"B Akinci","year":"2015","unstructured":"Akinci B, Koseoglu FD, Onay H, Yavuz S, Altay C, Simsir IY et al (2015) Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metabolism 64(9):1086\u20131095","journal-title":"Metabolism"},{"issue":"3","key":"3005_CR9","doi-asserted-by":"publisher","first-page":"e932","DOI":"10.1210\/clinem\/dgad700","volume":"109","author":"S Magno","year":"2024","unstructured":"Magno S, Ceccarini G, Corvillo F, Pelosini C, Gilio D, Paoli M et al (2024) Clinical characteristics of patients with acquired partial lipodystrophy: a multicenter retrospective study. J Clin Endocrinol Metab 109(3):e932\u2013e944","journal-title":"J Clin Endocrinol Metab"},{"key":"3005_CR10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf315","author":"C Kaewkrasaesin","year":"2025","unstructured":"Kaewkrasaesin C, Hwang M, Vasandani C, Brown RJ, Garg A (2025) Clinical features, metabolic and autoimmune derangements in acquired partial lipodystrophy (Barraquer-Simons syndrome). J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaf315","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"3005_CR11","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc14-S014","volume":"37","author":"DA American","year":"2014","unstructured":"American DA (2014) Standards of medical care in diabetes\u20132014. Diabetes Care 37(Suppl 1):S14-80","journal-title":"Diabetes Care"},{"issue":"25 Suppl 2","key":"3005_CR12","first-page":"S76","volume":"129","author":"RH Eckel","year":"2014","unstructured":"Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS et al (2014) 2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American college of cardiology\/American heart association task force on practice guidelines. Circulation 129(25 Suppl 2):S76-99","journal-title":"Circulation"},{"key":"3005_CR13","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection E (2001) Treatment of high blood cholesterol in a. executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA;285(19):2486\u201397","DOI":"10.1001\/jama.285.19.2486"},{"issue":"9","key":"3005_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM197602262940902","volume":"294","author":"JG Sissons","year":"1976","unstructured":"Sissons JG, West RJ, Fallows J, Williams DG, Boucher BJ, Amos N et al (1976) The complement abnormalities of lipodystrophy. N Engl J Med 294(9):461\u2013465","journal-title":"N Engl J Med"},{"key":"3005_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102979","volume":"137","author":"SL Coss","year":"2023","unstructured":"Coss SL, Zhou D, Chua GT, Aziz RA, Hoffman RP, Wu YL et al (2023) The complement system and human autoimmune diseases. J Autoimmun 137:102979","journal-title":"J Autoimmun"},{"issue":"24","key":"3005_CR16","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1001\/jama.2018.19329","volume":"320","author":"LA Lotta","year":"2018","unstructured":"Lotta LA, Wittemans LBL, Zuber V, Stewart ID, Sharp SJ, Luan J et al (2018) Association of genetic variants related to gluteofemoral vs abdominal fat distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors. JAMA 320(24):2553\u20132563","journal-title":"JAMA"},{"key":"3005_CR17","doi-asserted-by":"publisher","first-page":"1368966","DOI":"10.3389\/fnut.2024.1368966","volume":"11","author":"M Alser","year":"2024","unstructured":"Alser M, Naja K, Elrayess MA (2024) Mechanisms of body fat distribution and gluteal-femoral fat protection against metabolic disorders. Front Nutr 11:1368966","journal-title":"Front Nutr"},{"issue":"12","key":"3005_CR18","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M et al (2016) The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab 101(12):4500\u20134511","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3005_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.nefroe.2018.04.002","volume":"38","author":"F Corvillo","year":"2018","unstructured":"Corvillo F, Lopez-Trascasa M (2018) Acquired partial lipodystrophy and C3 glomerulopathy: dysregulation of the complement system as a common pathogenic mechanism. Nefrologia (Engl Ed) 38(3):258\u2013266","journal-title":"Nefrologia (Engl Ed)"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03005-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-03005-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03005-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:01:10Z","timestamp":1793397670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-03005-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3005"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-03005-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BA has run projects for and\/or served as a consultant, board member, steering committee member, and\/or speaker to Amryt Pharmaceuticals (now Chiesi Farmaceutici), Alnylam, Regeneron, ThirdRock Ventures, Astra Zeneca, Novonordisk, Boehringer Ingelheim, Sanofi, Bilim Ilac, ARIS, and Servier. EAO reports consulting with and receiving payments from Regeneron Pharmaceuticals, Inc. for scientific advising through payments made to University of Michigan. She also receives drug support and has an active contract with Regeneron Pharmaceuticals, Inc. for clinical trials. Grant support was also obtained. In the lipodystrophy space, she consults with, and receives clinical trial, grant or writing support from Amryt Pharmaceuticals (now part of Chiesi Rare Disease group) and Ionis Pharmaceuticals. She consults with Third Rock Ventures (now formed Marea Therapeutics) and Rejuvenate Bio and receives a grant from Rejuvenate Bio. She has IP rights to metreleptin manufactured by Amryt Pharmaceuticals (now part of Chiesi Rare Disease Group) and entitled to royalty payments. There is an invention disclosure filed for novel Mibavademab effects under review. Unrelated to lipodystrophy, she has ongoing clinical trial support from Novo Nordisk, Rhythm Pharmaceuticals, Fractyl, and Morphic Medical (formerly GI Dynamics). She received consultancy fees from Novo Nordisk in the last 36\u00a0months. Other authors report no conflicts of interest. Other authors report no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}